AWOL consortium identifies novel chemotypes in the search for drugs to combat lymphatic filariasis and onchocerciasis
Liverpool School of Tropical Medicine News Oct 05, 2017
Researchers from the AWOL consortium, based in the Research Centre for Drugs and Diagnostics at LSTM, have carried out whole cell screening of a 10,000 compound library. This has lead to the significant discovery of novel active chemotypes which have the potential to form new drugs, targeting Wolbachia, in the fight against lymphatic filariasis and onchocerciasis.
Funded by the Bill and Melinda Gates Foundation, the team have already screened thousands of existing drugs to look at their suitability to be used against LF and onchocerciasis and continue to have success with this approach. In this latest research, the results of which were published in the journal Science Advances, they have widened the search and identified six new chemical series which could be developed into completely novel anti-Wolbachia drugs that could translate into improved treatments for LF and onchocerciasis.
Dr Kelly Johnston is joint first author on the paper, with scientists at LSTM and the Department of Chemistry, University of Liverpool, and explains the significance of the work: ÂThere is an urgent need to discover a curative drug for these debilitating diseases and we know from proof-of-concept clinical trials that targeting Wolbachia is an effective and safe strategy. Here, we have built upon our previous screening campaigns to test 10,000 compounds from the BioFocus Soft Focus® group of compound libraries with the aim of exploring novel chemical space.Â
Initial validation screens led to 50 hits with comparable or better activity to the current gold standard treatment of doxycycline in reducing the Wolbachia loads in vitro. ÂSubsequent chemoinformatic analysis identified six anti-Wolbachia chemotypes with suitable drug-like qualities and scope for medicinal chemistry optimisation. Continued Dr Johnston: ÂWhile the paper presents all six, we focus on one of these templates which has real potential to translate into improved antibiotic treatments for LF and onchocerciasis, continuing A?WOLÂs drive to work towards clinical candidates that will positively impact on the lives of people in some of the worldÂs poorest communities.Â
Go to Original
Funded by the Bill and Melinda Gates Foundation, the team have already screened thousands of existing drugs to look at their suitability to be used against LF and onchocerciasis and continue to have success with this approach. In this latest research, the results of which were published in the journal Science Advances, they have widened the search and identified six new chemical series which could be developed into completely novel anti-Wolbachia drugs that could translate into improved treatments for LF and onchocerciasis.
Dr Kelly Johnston is joint first author on the paper, with scientists at LSTM and the Department of Chemistry, University of Liverpool, and explains the significance of the work: ÂThere is an urgent need to discover a curative drug for these debilitating diseases and we know from proof-of-concept clinical trials that targeting Wolbachia is an effective and safe strategy. Here, we have built upon our previous screening campaigns to test 10,000 compounds from the BioFocus Soft Focus® group of compound libraries with the aim of exploring novel chemical space.Â
Initial validation screens led to 50 hits with comparable or better activity to the current gold standard treatment of doxycycline in reducing the Wolbachia loads in vitro. ÂSubsequent chemoinformatic analysis identified six anti-Wolbachia chemotypes with suitable drug-like qualities and scope for medicinal chemistry optimisation. Continued Dr Johnston: ÂWhile the paper presents all six, we focus on one of these templates which has real potential to translate into improved antibiotic treatments for LF and onchocerciasis, continuing A?WOLÂs drive to work towards clinical candidates that will positively impact on the lives of people in some of the worldÂs poorest communities.Â
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries